Artiva Biotherapeutics (ARTV) to Release Earnings on Thursday

Key Points

• Artiva Biotherapeutics is set to announce its Q2 2025 earnings on August 7th, with analysts expecting a loss of ($0.77) per share.
• The company’s previous earnings report showed a loss of ($0.83) per share, which was below the consensus estimate of ($0.68).
• Six analysts currently rate Artiva Biotherapeutics as a buy, with an average price target of $17.80.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) is projected to announce its Q2 2025 earnings results on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.77) per share for the quarter.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.15). On average, analysts expect Artiva Biotherapeutics to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Artiva Biotherapeutics Stock Down 5.7%

NASDAQ ARTV traded down $0.17 during trading on Friday, reaching $2.83. 86,600 shares of the stock traded hands, compared to its average volume of 240,583. Artiva Biotherapeutics has a fifty-two week low of $1.47 and a fifty-two week high of $17.31. The stock's 50-day moving average price is $2.08 and its 200 day moving average price is $3.17.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. HC Wainwright raised shares of Artiva Biotherapeutics to a "buy" rating and set a $12.00 price objective on the stock in a research report on Wednesday, June 11th. Needham & Company LLC cut their price objective on shares of Artiva Biotherapeutics from $23.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Artiva Biotherapeutics currently has a consensus rating of "Buy" and an average target price of $17.80.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.